These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 36384172

  • 1. Setting limits for N-nitrosamines in drugs: A defined approach based on read-across and structure-activity relationship for N-nitrosopiperazine impurities.
    Dos Santos CEM, Dorta DJ, de Oliveira DP.
    Regul Toxicol Pharmacol; 2022 Dec; 136():105288. PubMed ID: 36384172
    [Abstract] [Full Text] [Related]

  • 2. N-nitrosamine impurity risk assessment in pharmaceuticals: Utilizing In vivo mutation relative potency comparison to establish an acceptable intake for NTTP.
    Powley MW, Sobol Z, Johnson GE, Clark RW, Dalby SM, Ykoruk BA, Galijatovic-Idrizbegovic A, Mowery MD, Escobar PA.
    Regul Toxicol Pharmacol; 2024 Sep; 152():105681. PubMed ID: 39067806
    [Abstract] [Full Text] [Related]

  • 3. Use of the benchmark-dose (BMD) approach to derive occupational exposure limits (OELs) for genotoxic carcinogens: N-nitrosamines.
    Blum K, FitzGerald R, Wilks MF, Barle EL, Hopf NB.
    J Appl Toxicol; 2023 Aug; 43(8):1183-1200. PubMed ID: 36840679
    [Abstract] [Full Text] [Related]

  • 4. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
    Kruhlak NL, Schmidt M, Froetschl R, Graber S, Haas B, Horne I, Horne S, King ST, Koval IA, Kumaran G, Langenkamp A, McGovern TJ, Peryea T, Sanh A, Siqueira Ferreira A, van Aerts L, Vespa A, Whomsley R.
    Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
    [Abstract] [Full Text] [Related]

  • 5. Simultaneous determination of low molecular weight nitrosamines in pharmaceutical products by fast gas chromatography mass spectrometry.
    Kalauz A, Tiringer KV, Horváth V, Kapui I.
    J Chromatogr A; 2023 Oct 11; 1708():464323. PubMed ID: 37696123
    [Abstract] [Full Text] [Related]

  • 6. Presence of nitrosamine impurities in medicinal products.
    Sedlo I, Kolonić T, Tomić S.
    Arh Hig Rada Toksikol; 2021 Mar 01; 72(1):1-5. PubMed ID: 33787187
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Analysis of selected drug formulations for volatile nitrosamines.
    Dawson BA, Lawrence RC.
    J Assoc Off Anal Chem; 1987 Mar 01; 70(3):554-6. PubMed ID: 3610969
    [Abstract] [Full Text] [Related]

  • 11. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography.
    Schmidtsdorff S, Schmidt AH.
    J Pharm Biomed Anal; 2019 Sep 10; 174():151-160. PubMed ID: 31174128
    [Abstract] [Full Text] [Related]

  • 12. Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used Medications.
    Li K, Ricker K, Tsai FC, Hsieh CJ, Osborne G, Sun M, Marder ME, Elmore S, Schmitz R, Sandy MS.
    Int J Environ Res Public Health; 2021 Sep 08; 18(18):. PubMed ID: 34574388
    [Abstract] [Full Text] [Related]

  • 13. Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosamines.
    Thomas R, Thresher A, Ponting DJ.
    Regul Toxicol Pharmacol; 2021 Apr 08; 121():104875. PubMed ID: 33556416
    [Abstract] [Full Text] [Related]

  • 14. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines.
    Snodin DJ.
    Regul Toxicol Pharmacol; 2023 Jun 08; 141():105403. PubMed ID: 37116739
    [Abstract] [Full Text] [Related]

  • 15. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
    Wichitnithad W, Nantaphol S, Noppakhunsomboon K, Rojsitthisak P.
    Saudi Pharm J; 2023 Feb 08; 31(2):295-311. PubMed ID: 36942272
    [Abstract] [Full Text] [Related]

  • 16. Metabolism of carcinogenic nitrosamines by rat nasal mucosa and the effect of diallyl sulfide.
    Hong JY, Smith T, Lee MJ, Li WS, Ma BL, Ning SM, Brady JF, Thomas PE, Yang CS.
    Cancer Res; 1991 Mar 01; 51(5):1509-14. PubMed ID: 1997191
    [Abstract] [Full Text] [Related]

  • 17. Intake of volatile nitrosamines by Chinese residents in different provinces via food and drinking water.
    Li X, Bei E, Qiu Y, Xiao H, Wang J, Lin P, Zhang X, Chen C.
    Sci Total Environ; 2021 Feb 01; 754():142121. PubMed ID: 32911156
    [Abstract] [Full Text] [Related]

  • 18. Quantum Mechanical Assessment of Nitrosamine Potency.
    De S, Thapa B, Sayyed FB, Frank SA, Cornwell PD, Jolly RA.
    Chem Res Toxicol; 2024 Jun 17; 37(6):1011-1022. PubMed ID: 38804898
    [Abstract] [Full Text] [Related]

  • 19. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
    Thresher A, Foster R, Ponting DJ, Stalford SA, Tennant RE, Thomas R.
    Regul Toxicol Pharmacol; 2020 Oct 17; 116():104749. PubMed ID: 32777431
    [Abstract] [Full Text] [Related]

  • 20. Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism.
    Graves RJ, Swann PF.
    Biochem Pharmacol; 1993 Mar 09; 45(5):983-9. PubMed ID: 8461051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.